ReviewCardiovascular drugs and therapy2013
Role of late sodium channel current block in the management of atrial fibrillation.
Review in Cardiovascular drugs and therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 50 citations in OpenAlex.
- Plant-derived compounds as potential candidates for atrial fibrillation drug discovery: A review on phytochemicals with atrial-selective activity.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Review
- Ranolazine Unveiled: Rediscovering an Old Solution in a New Light.Journal of clinical medicine · 2024Review
- Association between Empagliflozin Use and Electrocardiographic Changes.Clinics and practice · 2022Article
- Moricizine prevents atrial fibrillation by late sodium current inhibition in atrial myocytes.Journal of thoracic disease · 2022Article
- Local Anesthetic Like Inhibition of the Cardiac NaJournal of experimental pharmacology · 2022Article
- Role of Ranolazine in the Prevention and Treatment of Atrial Fibrillation in Patients with Left Ventricular Systolic Dysfunction: A Meta-Analysis of Randomized Clinical Trials.Diseases (Basel, Switzerland) · 2021Article
- Phospho-ablation of cardiac sodium channel NaInternational journal of obesity (2005) · 2021Article
- Fibroblast Growth Factor 1 Reduces Pulmonary Vein and Atrium ArrhythmogenesisFrontiers in cardiovascular medicine · 2021Article
- Investigational Anti-Atrial Fibrillation Pharmacology and Mechanisms by Which Antiarrhythmics Terminate the Arrhythmia: Where Are We in 2020?Journal of cardiovascular pharmacology · 2020Review
- Do age-associated changes of voltage-gated sodium channel isoforms expressed in the mammalian heart predispose the elderly to atrial fibrillation?World journal of cardiology · 2020Review
- Late Sodium Current Inhibitors as Potential Antiarrhythmic Agents.Frontiers in pharmacology · 2020Review
- Mechanisms of Action of the KCa2-Negative Modulator AP30663, a Novel Compound in Development for Treatment of Atrial Fibrillation in Man.Frontiers in pharmacology · 2020Article
- Homocysteine-induced electrical remodeling via the mediation of IPAmerican journal of translational research · 2020Article
- Protein Phosphatase 2A Regulates Cardiac NaCirculation research · 2019Article
- Late sodium current associated cardiac electrophysiological and mechanical dysfunction.Pflugers Archiv : European journal of physiology · 2018Review
- Classification and reporting of severity experienced by animals used in scientific procedures: FELASA/ECLAM/ESLAV Working Group report.Laboratory animals · 2018Article
- Effects of Amiodarone and N-desethylamiodarone on Cardiac Voltage-Gated Sodium Channels.Frontiers in pharmacology · 2016Article
- Atrial fibrillation in patients with diabetes: molecular mechanisms and therapeutic perspectives.Cardiovascular diagnosis and therapy · 2015Review
- Short-course of ranolazine prevents postoperative atrial fibrillation following coronary artery bypass grafting and valve surgeries.Clinical research in cardiology : official journal of the German Cardiac Society · 2015Article
- The vernakalant story: how did it come to approval in Europe and what is the delay in the U.S.A?Current cardiology reviews · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The anti-arrhythmic efficacy of the late sodium channel current (late I(Na)) inhibition has been convincingly demonstrated in the ventricles, particularly under conditions of prolonged ventricular repolarization. The value of late I(Na) block in the setting of atrial fibrillation (AF) remains poorly investigated. All sodium channel blockers inhibit both peak and late I(Na) and are generally more potent in inhibiting late vs. early I(Na). Selective late I(Na) block does not prolong the effective refractory period (ERP), a feature common to practically all anti-AF agents. Although the late I(Na) blocker ranolazine has been shown to be effective in suppression of AF, it is noteworthy that at concentrations at which it blocks late I(Na) in the ventricles, it also potently blocks peak I(Na) in the atria, thus causing rate-dependent prolongation of ERP due to development of post-repolarization refractoriness. Late I(Na) inhibition in atria is thought to suppress intracellular calcium (Ca(i))-mediated triggered activity, secondary to a reduction in intracellular sodium (Na(i)). However, agents that block late I(Na) (ranolazine, amiodarone, vernakalant, etc) are also potent atrial-selective peak I(Na) blockers, so that the reduction of Na(i) loading in atrial cells by these agents can be in large part due to the block of peak I(Na). The impact of late I(Na) inhibition is reduced by the abbreviation of the action potential that occurs in AF patients secondary to electrical remodeling. It stands to reason that selective late I(Na) block may contribute more to inhibition of Ca(i)-mediated triggered activity responsible for initiation of AF in clinical pathologies associated with a prolonged atrial APD (such as long QT syndrome). Additional studies are clearly needed to test this hypothesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.